Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance).

doi:10.1158/1078-0432.CCR-21-2386

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance).

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jul 2022

Nixon Andrew B, Halabi Susan, Liu Yingmiao, Starr Mark D, Brady John C, Shterev Ivo, Luo Bin, Hurwitz Herbert I, Febbo Phillip G, Rini Brian I, Beltran Himisha, Small Eric J, Morris Michael J, George Daniel J

Abstract excerpt

PURPOSE: CALGB 90206 was a phase III trial of 732 patients with metastatic renal cell carcinoma (mRCC) comparing bevacizumab plus IFNα (BEV + IFN) with IFNα alone (IFN). No difference in overall survival (OS) was observed. Baseline samples were analyzed to identify predictive biomarkers for survival benefit. PATIENTS AND METHODS: A total of 32 biomarkers were assessed in 498 consenting patients randomly assigned...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bevacizumab

Share to Biomarkers

Share to Carcinoma, Renal Cell

Share to Disease-Free Survival

Share to Interferon-alpha

Share to Interleukin-6

Share to Kidney Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 34965953
DOI: 10.1158/1078-0432.CCR-21-2386
PMCID: PMC9240110

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance).PMID 34965953Read ↗

Bevacizumab: direct anti-VEGF therapy in renal cell carcinoma.Semantic proximity Read ↗

Prognosis of metastatic renal cell carcinoma with first-line interferon-α therapy in the era of molecular-targeted therapy.Semantic proximity Read ↗

Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.Semantic proximity Read ↗

[Biomarkers of response to molecular targeted therapy in renal cell carcinoma].Semantic proximity Read ↗

Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy.Semantic proximity Read ↗

Molecular markers to predict response to therapy.Semantic proximity Read ↗

Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance).Semantic proximity Read ↗

Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms.Semantic proximity Read ↗

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.Semantic proximity Read ↗

Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting.Semantic proximity Read ↗

Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma.Semantic proximity Read ↗

Biomarkers for evaluating racial disparities in clinical outcome in patients with renal cell carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.